The hepatoprotective and hypolipidemic effects of Spirulina ( Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study

Elias E Mazokopakis, Maria G Papadomanolaki, Andreas A Fousteris, Dimitrios A Kotsiris, Ioannis M Lampadakis, Emmanuel S Ganotakis, Elias E Mazokopakis, Maria G Papadomanolaki, Andreas A Fousteris, Dimitrios A Kotsiris, Ioannis M Lampadakis, Emmanuel S Ganotakis

Abstract

Background: A pilot study was conducted to determine the effects of Spirulina (Arthrospira platensis) on Cretan patients with non-alcoholic fatty liver disease (NAFLD). Spirulina is a filamentous cyanobacterium taken as a dietary supplement.

Methods: Fifteen adult Cretan outpatients (13 men), median age 48 (range: 29-62) years, with NAFLD were orally supplemented with 6 g of Spirulina (Greek production) per day for six months. Anthropometric characteristics (height, weight, waist circumference), systolic and diastolic blood pressure, complete blood count, biochemical assessments, homeostasis model assessment of insulin resistance (HOMA-IR) index, health-related quality of life and abdominal sonographic findings were recorded and measured, before and after Spirulina supplementation.

Results: At the end of the 6-month intervention period, the mean levels of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, triglycerides, low-density lipoprotein-cholesterol, total cholesterol, and the ratio of total cholesterol to high-density lipoprotein cholesterol were significantly decreased: 38.5%, 37.5%, 26.7%, 24.8%, 9.6%, 9.1%, and 13.5% respectively, whereas the mean levels of high-density lipoprotein-cholesterol and hemoglobin were significantly increased: 4.2% and 4.1% respectively. Spirulina supplementation resulted also in a significant reduction in weight and HOMA-IR index (8.1% and 19.6% respectively) and a significant improvement in health-related quality of life scale. No changes in sonographic findings were observed.

Conclusion: Spirulina supplementation at a high dosage of 6 g daily in NAFLD patients has strong and multiple beneficial metabolic effects and improves their health-related quality of life.

Keywords: Arthrospira; NAFLD; lipids; liver; spirulina; steatosis.

Conflict of interest statement

Conflict of Interest: None

References

    1. Mazokopakis EE, Starakis IK, Papadomanolaki MG, Mavroeidi NG, Ganotakis ES. The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study. J Sci Food Agric. 2013;94:432–437.
    1. Mazokopakis EE, Karefilakis CM, Tsartsalis AN, Milkas AN, Ganotakis ES. Acute rhabdomyolysis caused by Spirulina (Arthrospira platensis) Phytomedicine. 2008;15:525–527.
    1. Yakoot M, Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC Gastroenterol. 2012;12:32.
    1. Karkos PD, Leong SC, Karkos CD, Sivaji N, Assimakopoulos DA. Spirulina in clinical practice: evidence-based human applications. Evid Based Complement Alternat Med 2011. 2011:531053.
    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231.
    1. Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712–1723.
    1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438.
    1. Uslusoy HS, Nak SG, Gülten M, Biyikli Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol. 2009;15:1863–1868.
    1. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci. 2005;50:171–180.
    1. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:360–369.
    1. Mavrogiannaki AN, Migdalis IN. Non-alcoholic fatty liver disease, diabetes mellitus and cardiovascular disease. Newer data Hellenic J Atherosclerosis. 2013;4:96–103.
    1. Söderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;2:595–602.
    1. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011;56:3439–3449.
    1. WHO (World Health Organization) Geneva, Switzerland: World Health Organization; 1998. Obesity: preventing and managing the global epidemic. WHO/NUT/NCD/98.1.
    1. International Diabetes Federation (IDF) consensus worldwide defi nition of the Metabolic Syndrome. International Diabetes Federation 2006. Available on .
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
    1. Lauer RM, Lee J, Clarke WR. Factors affecting the relationship between childhood and adult cholesterol levels: the Muscatine Study. Pediatrics. 1988;82:309–318.
    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Suppl 1):S67–S74.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
    1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497.
    1. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45:295–300.
    1. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol. 2001;96:579–583.
    1. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007;11:37–54. viii.
    1. Mazhar SM, Shiehmorteza M, Sirlin CB. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol. 2009;7:135–140.
    1. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med. 1983;139:43–50.
    1. Ferreira-Hermosillo A, Torres-Duran PV, Juarez-Oropeza MA. Hepatoprotective effects of Spirulina maxima in patients with non-alcoholic fatty liver disease: a case series. J Med Case Rep. 2010;4:103.
    1. Deng R, Chow TJ. Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina. Cardiovasc Ther. 2010;28:e33–e45.
    1. Lee EH, Park JE, Choi YJ, Huh KB, Kim WY. A randomized study to establish the effects of Spirulina in type 2 diabetes mellitus patients. Nutr Res Pract. 2008;2:295–300.
    1. Park HJ, Lee YJ, Ryu HK, Kim MH, Chung HW, Kim WY. A randomized double-blind, placebo controlled study to establish the effects of Spirulina in elderly Koreans. Ann Nutr Metab. 2008;52:322–328.
    1. Kim WY, Kim MH. The change of lipid metabolism and immune function caused by antioxidant material in the hypercholesterolemin elderly women in Korea. Korean J Nutr. 2005;38:67–75.
    1. Torres-Durán PV, Miranda-Zamora R, Paredes-Carbajal MC, Mascher D, Díaz-Zagoya JC, Juárez-Oropeza MA. Spirulina maxima prevents induction of fatty liver by carbon tetrachloride in the rat. Biochem Mol Biol Int. 1998;44:787–793.
    1. Torres-Durán PV, Miranda-Zamora R, Paredes-Carbajal MC, Mascher D, Blé-Castillo J, Díaz-Zagoya JC, Juárez-Oropeza MA. Studies on the preventive effect of Spirulina maxima on fatty liver development induced by carbon tetrachloride, in the rat. J Ethnopharmacol. 1999;64:141–147.
    1. Torres-Durán PV, Paredes-Carbajal MC, Mascher D, Zamora-González J, Díaz-Zagoya JC, Juárez-Oropeza MA. Protective effect of Arthrospira maxima on fatty acid composition in fatty liver. Arch Med Res. 2006;37:479–483.
    1. Blé-Castillo JL, Rodríguez-Hernández A, Miranda-Zamora R, Juárez-Oropeza MA, Díaz-Zagoya JC. Arthrospira maxima prevents the acute fatty liver induced by the administration of simvastatin, ethanol and a hypercholesterolemic diet to mice. Life Sci. 2002;70:2665–2673.
    1. Rodríguez-Hernández A, Blé-Castillo JL, Juárez-Oropeza MA, Díaz-Zagoya JC. Spirulina maxima prevents fatty liver formation in CD-1 male and female mice with experimental diabetes. Life Sci. 2001;69:1029–1037.
    1. Kato T, Takemoto K. Effects of Spirulina on hypercholesterolemia and fatty liver in rats. Japan Nutr Foods Assoc J. 1984;37:321.
    1. Vadiraja BB, Gaikwad NW, Madyastha KM. Hepatoprotective effect of C-phycocyanin:protection for carbon tetrachloride and R-(+)-pulegone-mediated hepatotoxicty in rats. Biochem Biophys Res Commun. 1998;249:428–431.
    1. Premkumar K, Abraham SK, Santhiya ST, Ramesh A. Protective effect of Spirulina fusiformis on chemical-induced genotoxicity in mice. Fitoterapia. 2004;75:24–31.
    1. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010;28:179–185.
    1. Weaterbacka J, Lammi K, Hakkinen A. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab. 2005;90:2804–2809.
    1. Browning J, Davis J, Saboorian M. A low carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. Hepatology. 2006;44:487–488.
    1. Assy N, Kaita K, Mymin D, Levy C, Roser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929–1934.
    1. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755–765.
    1. Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci. 2012;57:1773–1781.
    1. Nagaoka S, Shimizu K, Kaneko H, et al. A novel protein C-phycocyanin plays a crucial role in the hypocholesterolemic action of Spirulina platensis concentrate in rats. J Nutr. 2005;135:2425–2430.
    1. Han LK, Li DX, Xiang L, et al. Isolation of pancreatic lipase activity-inhibitory component of Spirulina platensis and it reduce postprandial triacylglycerolemia. Yakugaku Zasshi. 2006;126:43–49.
    1. Ng TW, Watts GF, Barrett PH, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care. 2007;30:2945–2950.
    1. Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord. 2002;26(Suppl 4):S25–S28.
    1. de Leiva A. What are the benefits of moderate weight loss? Exp Clin Endocrinol Diabetes. 1998;106(Suppl 2):10–13.
    1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.
    1. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.
    1. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–107.
    1. Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol. 2005;43:1060–1066.
    1. Hickman I, Jonsson J, Prins J. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53:413–419.
    1. Petersen K, Dufour S, Befroy D. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603–608.
    1. Al-Jiffri O, Al-Sharif FM, Abd El-Kader SM, Ashmawy EM. Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver. Afr Health Sci. 2013;13:667–672.
    1. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PHR. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab. 1999;84:2854–2861.
    1. Ballinger AB, Clark ML. L-phenylalanine releases cholecystokinin (CCK) and is associated with reduced food intake in humans: evidence for a physiological role of CCK in control of eating. Metabolism. 1994;43:735–738.
    1. Gibbs J, Falasco JD, McHugh PR. Cholecystokinin-decreased food intake in rhesus monkeys. Am J Physiol. 1976;230:15–18.
    1. Silverstone T, Goodall E. The clinical pharmacology of appetite suppressant drugs. Int J Obes. 1984;8(Suppl 1):23–33.
    1. Mani UV, Iyer UM, Dhruv SA, Mani IU, Sharma KS. Gershwin ME, Amha Belay. Spirulina in human nutrition and health. CRC Press, Taylor & Francis Group; 2008. Therapeutic utility of Spirulina; pp. 71–99.
    1. Mani U, Sadliwala A, Iyer U, Parikh P. The effect of spirulina supplementation on blood haemoglobin levels of anaemic adult girls. J Food Sci Technol. 2000;37:642–644.
    1. Kurdikeri SM. Dharwad: Thesis,University of Agricultural Sciences; 2006. Effect of spirulina on lipid profile of hyperlipidemics.
    1. Kauser F, Parveen S. Effect of spirulina as a nutritional supplement on malnourished children. Indian J Nutr Diet. 2001;38:269–272.
    1. van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved1H MR spectroscopy. Radiology. 2010;256:159–168.
    1. Fabbrini E, Conte C, Magkos F. Methods for assessing intrahepatic fat content and steatosis. Curr Opin Clin Nutr Metab Care. 2009;12:474–481.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere